We will be comparing the differences between Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) and CRISPR Therapeutics AG (NASDAQ:CRSP) as far as profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Rhythm Pharmaceuticals Inc.||22||-0.36||20.69M||-2.61||0.00|
|CRISPR Therapeutics AG||51||0.00||34.37M||-3.74||0.00|
Table 1 shows the gross revenue, earnings per share and valuation for Rhythm Pharmaceuticals Inc. and CRISPR Therapeutics AG.
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|Rhythm Pharmaceuticals Inc.||95,039,044.56%||-33.9%||-32.5%|
|CRISPR Therapeutics AG||67,207,665.23%||-50.9%||-39.8%|
The current Quick Ratio of Rhythm Pharmaceuticals Inc. is 18.3 while its Current Ratio is 18.3. Meanwhile, CRISPR Therapeutics AG has a Current Ratio of 15.8 while its Quick Ratio is 15.8. Rhythm Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than CRISPR Therapeutics AG.
Rhythm Pharmaceuticals Inc. and CRISPR Therapeutics AG Ratings and Recommendations are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Rhythm Pharmaceuticals Inc.||0||0||1||3.00|
|CRISPR Therapeutics AG||0||0||4||3.00|
Rhythm Pharmaceuticals Inc.’s upside potential is 54.76% at a $34 average price target. Competitively the average price target of CRISPR Therapeutics AG is $66.5, which is potential -5.42% downside. Based on the analysts view we can conclude, Rhythm Pharmaceuticals Inc. is looking more favorable than CRISPR Therapeutics AG.
Insider and Institutional Ownership
The shares of both Rhythm Pharmaceuticals Inc. and CRISPR Therapeutics AG are owned by institutional investors at 91.3% and 50% respectively. Insiders held roughly 1.7% of Rhythm Pharmaceuticals Inc.’s shares. Comparatively, CRISPR Therapeutics AG has 2% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Rhythm Pharmaceuticals Inc.||-7.09%||-11.98%||-23.09%||-27.3%||-35.49%||-28.39%|
|CRISPR Therapeutics AG||3.15%||6.25%||30.58%||57.23%||7.51%||77.42%|
For the past year Rhythm Pharmaceuticals Inc. had bearish trend while CRISPR Therapeutics AG had bullish trend.
Rhythm Pharmaceuticals Inc. beats on 7 of the 11 factors CRISPR Therapeutics AG.
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, AlstrÃ¶m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is based in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.